Responses
Extended report
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 14 November 2005
- Published on: 14 November 2005Pre-treatment screening takes place before anti-TNF is prescribedShow More
Dear Editor
In their article: Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists (and likewise in their subsequent article: Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists) Askling et al. compare occurrence rates for malignancies between different cohorts...
Conflict of Interest:
None declared.